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Background: The shortage of organs is a major hurdle in kidney transplantation, and one
solution to the problem is to extend the age of the donor. However, organs from older donors
are often discarded due to the macroscopic appearance of the parenchyma or major vessels.
On the other hand, a large number of elderly patients are potential candidates for kidney
transplantation, while many kidneys from elderly deceased donors are discarded due to a
lack of age-matched recipients. In addition, a large number are often discarded due to the
lack of compatible recipients among elderly patients undergoing chronic dialysis. A possible
solution to avoid this wastage of kidneys potentially suitable for transplantation could be
the performance of preemptive kidney transplantation (PKT) in carefully selected elderly
patients. PKT improves graft and patient survival compared to other renal replacement
therapy options. There is no information about PKT in elderly patients receiving kidneys
from elderly deceased donors.
Methods: From 2007 to 2012, we performed a prospective observational study comparing 26
elderly patients receiving PKT with a control group of 26 elderly patients receiving a ﬁrst
transplant after prior dialysis.
Results: Mean age of recipients was 74.3 ± 2.9 years and mean age of donors was 73.8 ±
4.1 years. Induction immunosuppression was similar in both groups. Death-censored graft
survival was 96% in the PKT group and 68% in the control group (p = 0.02), at 5 years after
transplantation. Immediate and delayed graft function occurred in 92% and 3.8%, respec-
tively, of patients in the PKT group and 53% and 34.6% of patients in the control group
(p  = 0.005). Acute rejection was signiﬁcantly more frequent in PKT patients (23.1% vs 3.8%,
p = 0.043). At the end of follow-up time 35.5 ± 20.1 months, the glomerular ﬁltration rate was
similar in both groups (42.2 ± 11.7 vs 41.7 ± 11.2 ml/min, p-value = 0.72). Patient survival
was similar in the two groups.
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Conclusions: Elderly patients with end stage of renal disease non-dialysis may beneﬁt from
PKT elderly deceased donors whose kidneys were to be discarded for there are not patients
in  the waiting list.
© 2015 The Authors. Published by Elsevier España, S.L.U. on behalf of Sociedad Española de
Nefrología. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Trasplante  renal  prediálisis  en  pacientes  ancianos  con  rin˜ones
descartados  de  donantes  de  edad  muy  avanzada:  una  buena  alternativa
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Antecedentes: La escasez de órganos constituye una importante diﬁcultad para los trasplantes
renales, y una posible solución del problema está en ampliar el margen de edad aceptado
para los donantes. Sin embargo, los órganos de donantes de edad avanzada se desechan
con frecuencia debido al aspecto macroscópico del parénquima o de los vasos sanguíneos
principales. Por otro lado, hay un gran número de pacientes ancianos que son posibles
candidatos a un trasplante renal, mientras que muchos rin˜ones de donantes ancianos fa-
llecidos se desechan porque no hay receptores de una edad similar. Además, a menudo se
desecha un gran número de órganos a causa de la falta de receptores compatibles entre los
pacientes ancianos en diálisis crónica. Una posible solución para evitar que se desperdicien
estos rin˜ones que pueden ser apropiados para un trasplante sería llevar a cabo un trasplante
renal prediálisis (TRP) en pacientes ancianos cuidadosamente seleccionados. El TRP mejora
la supervivencia del órgano trasplantado y del paciente, en comparación con otras opciones
de  terapia sustitutiva renal. No disponemos de información acerca del TRP en pacientes
ancianos a los que se trasplantan rin˜ones de donantes ancianos fallecidos.
Métodos: De 2007 a 2012 llevamos a cabo un estudio prospectivo observacional en el que se
compararon 26 pacientes ancianos que recibieron un TRP con un grupo de control formado
por 26 pacientes ancianos a los que se practicó un primer trasplante después de una diálisis
previa.
Resultados: La media de edad de los receptores fue de 74,3 ± 2,9 an˜os y la de los donantes
de 73,8 ± 4,1 an˜os. La inmunosupresión de inducción fue similar en los dos grupos de
tratamiento. La supervivencia del órgano, con censura para el análisis estadístico a la muerte
del  paciente, fue del 96% en el grupo de TRP y del 68% en el grupo de control (p = 0,02),
5  an˜os después del trasplante. Hubo una función inmediata y tardía del rin˜ón trasplantado
en el 92% y 3,8% de los pacientes, respectivamente, en el grupo de TRP, y en el 53% y 34,6%
de  los pacientes en el grupo de control (p = 0,005). El rechazo agudo fue signiﬁcativamente
más  frecuente en los pacientes a los que se practicó un TRP (23,1% frente a 3,8%, p = 0,043).
Al ﬁnal del periodo de seguimiento de 35,5 ± 20,1 meses, la ﬁltración glomerular fue similar
en ambos grupos (42,2 ± 11,7 frente a 41,7 ± 11,2 ml/min, valor de p = 0,72). La supervivencia
de los pacientes fue también similar en los dos grupos.
Conclusiones: En los pacientes ancianos con una enfermedad renal terminal no dializa-
dos, puede resultar beneﬁcioso un TRP de donantes ancianos fallecidos cuyos rin˜ones se
desecharían si no hubiera pacientes en lista de espera.
©  2015 The Authors. Publicado por Elsevier España, S.L.U. en nombre de Sociedad Española
de Nefrología. Este es un artículo Open Access bajo la licencia CC BY-NC-ND
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
In recent years, the number of patients older than 65 years
with end stage renal disease (ESRD) has increased1 and is now
the fastest growing patient population requiring renal replace-
ment therapy in both Europe and the United States. Kidney
transplantation improves life expectancy and quality of life in
patients of all ages with ESRD2,3 and is an attractive option for
elderly patients, in whom it confers lower mortality rates and
improved quality of life compared to dialysis.4,5 However, a
vast majority of kidney transplants in elderly patients are per-
formed after a period of chronic dialysis, and in those elderly
patients in whom a preemptive kidney transplant (PKT) is per-
formed the organ comes from a living donor. No experience
about PKT using kidneys from elderly deceased donors has
so far been reported. This lack of information is important
because PKT is the ideal treatment for patients with advanced
chronic kidney disease (CKD). Not only does PKT obviate the
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need for vascular access or the placement of a peritoneal
catheter, thus reducing the cost of dialysis and improving
the quality of life of the patient,6 but more  importantly, it
also extends the survival of patients compared to other ther-
apeutic options and attains superior outcomes in terms of
both graft and patient survival than transplantation after prior
dialysis.7,8 In fact, time spent on dialysis prior to transplan-
tation has been shown to be one of the most signiﬁcant
factors affecting the outcome of kidney transplantation.9,10
On the other hand, the onset of chronic dialysis (building of
a successful vascular access for hemodialysis, or peritoneal
catheter placement) is more  challenging in elderly patients,
thus reinforcing the theoretical advantages of PKT in these
patients.
The shortage of organs is a limiting factor for kidney trans-
plantation in all age ranges and has led to the use of expanded
criteria donors, including those aged over 60 years.4,11 In
Spain, 50% of donors are older than 60 and up to 25% are
older than 70. Kidney transplantation with expanded criteria
donor organs has been associated with longer survival than
dialysis,3 but data are limited on elderly patients. Although
graft survival is generally poorer with older than with younger
donors, when kidneys are selected based on renal function,
macroscopic examination and histological information, excel-
lent results can still be attained.12 In spite of the shortage of
organs, a signiﬁcant number of kidneys from older deceased
donors are not used because of donor hypertension, dia-
betes or renal failure, macroscopic or microscopic alterations
in the kidney, or importantly, the lack of a suitable recipi-
ent. In a previous study, we  found that more  than 50% of
kidneys from older donors were discarded mainly because
there was  no potentially compatible recipient on the waiting
list.13
In order to avoid the wasting of kidneys from deceased
elderly donors due to the lack of compatible recipients among
elderly patients undergoing chronic dialysis, we  created in
January 2007 a waiting list of predialysis elderly patients to
receive these kidneys. Here we report our experience with
this cohort of elderly patients receiving PKTs from elderly
deceased donors and compare it with that of a cohort of elderly
patients who  received a kidney transplant after the onset of
chronic dialysis.
Patients  and  methods
Patients  and  study  design
This is a longitudinal, prospective, observational study of
patients undergoing PKT at a single center. From January
2007 to December 2012, we consecutively enrolled 26 patients
undergoing PKT at the Department of Nephrology and Trans-
plantation in the Hospital 12 de Octubre, Madrid, Spain.
Inclusion criteria were age >65 years, advanced CKD, GFR
according to the four-variable MDRD < 15 ml/min, progression
of renal failure (25% decrease in GFR over the past 12 months),
no prior kidney transplant, and non-hyperimmunized status.
Exclusion criteria were stable renal function (<25% decrease
in GFR), active tumor, multiple = “multiple” aortoiliac calciﬁ-
cations, and medical and/or surgical contraindications. The
study was approved by the Institutional Review Board of the
Hospital 12 de Octubre, and all patients gave their signed
informed consent.
The control group comprised an additional 26 patients aged
>65 years who received a ﬁrst kidney transplant after the onset
of chronic dialysis. Thirteen (50%) of the controls received
paired kidneys from the same donors as the PKT patients; the
remaining recipients were selected as controls because their
transplants were performed immediately before or after the
PKT patients.
The following donor variables were recorded: age, gender,
ABO blood group, BMI, history of hypertension or diabetes
mellitus, cytomegalovirus (CMV) immunization, viral hepatic
infections, sepsis, cause of death, serum creatinine (Scr) levels
at procurement, estimated GFR according to the four-variable
MDRD, cold ischemia time, warm ischemia time, kidney
anatomy, and perfusion solution. The following recipient
characteristics were recorded: age, underlying renal disease,
time on dialysis, serology, immunological data, BMI, arterial
hypertension, hyperlipidemia, diabetes, pre-transplant car-
diovascular disease, waiting time for kidney transplant, type
of dialysis (hemodialysis or peritoneal dialysis), panel-reactive
antibodies, HLA-A, HLA-B, and HLA-DR mismatches, and
baseline immunosuppression. Post-surgical complications,
infections, tumors, modiﬁcation of immunosuppression, and
length of hospital stay were also recorded. Renal func-
tion and proteinuria were recorded weekly during the ﬁrst
month, every three months during the ﬁrst year, and annually
thereafter.
Main outcomes were graft survival and patient survival.
Secondary outcomes were immediate graft function, delayed
graft function (deﬁned as the need for at least one hemodial-
ysis session during the ﬁrst week post-transplantation), and
biopsy-proven acute rejection (BPAR). Causes of graft loss and
causes of death were also recorded. Graft survival was calcu-
lated from the date of transplantation until death, return to
dialysis, or the end of the study period. Death-censored graft
survival was calculated when death occurred with functioning
graft.
Statistics
Continuous variables were expressed as mean and standard
deviation or as median and range, as appropriate. Categori-
cal variables were expressed as frequencies or percentages.
Student’s t test or the Mann–Whitney U test was used to com-
pare continuous variables. Qualitative variables were analyzed
with the chi-squared test with Yates’ correction or Fisher’s
exact test. Graft and patient survival were calculated using
the Kaplan–Meier method and compared with the log-rank
test. Univariate and multivariate regression analyses (with a
backward stepwise procedure) were performed with the Cox
proportional hazards model to obtain hazard ratios (HRs) with
their 95% conﬁdence intervals (CIs). All factors with p < 0.05
in the univariate analysis and all clinically relevant factors
with p < 0.2 in the univariate analysis were included in the
multivariate model. Signiﬁcance was set at p < 0.05. All sta-
tistical analyses were performed with IBM SPSS Statistics for
Windows version 15.0.
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Results
Donor  and  recipient  characteristics
Fifty-two patients were enrolled in the study: 26 (11 women, 15
men) PKTs and 26 (13 women, 13 men) controls. Table 1 shows
the baseline characteristics of the transplant recipients. Mean
age was 74.3 ± 2.9 years (range 68–81 years) in the PKT group
and 73.4 ± 4.1 years (range 65–79 years) in the control group.
All 26 patients in the PKT group had hypertension, compared
to only 18 (69.2%) in the control group (p = 0.02). There were
no other signiﬁcant differences in baseline characteristics
between the two groups (Table 1). In the control group,
the interval between onset of chronic dialysis and kidney
transplantation was 15 ± 14 months (range 3–62). Twenty-ﬁve
recipients (96.2%) in each group received quadruple immuno-
suppressive therapy with interleukin-2 receptor antagonists,
low doses of calcineurin inhibitors, mycophenolate mofetil,
and corticosteroids. Induction treatment consisted of basilix-
imab, an anti-intcrleukin-2 receptor monoclonal antibody, in
50 patients (96%) and of timoglobulin in two (4%).
Table 1 displays the baseline characteristics of the
donors. Median donor age was 73.8 ± 4.1 years (range, 65–
80 years) in the PKT group and 74.4 ± 5.1 years (range
65–84 years) in the control group. There were no signiﬁcant
differences in baseline characteristics between the two
groups. The median Scr level at the time of procurement was
0.7 mg/dl (range 0.5–1.1 mg/dl) in both groups. Median esti-
mated GFR was 90.4 ± 19.6 ml/min/1.73 m2 in the PKT group
and 94.2 ± 24.3 ml/min/1.73 m2 in the control group. Kidney
biopsy was performed in 16 donors in the PKT group and in 20
Table 1 – Baseline recipient and donor characteristics.
Recipient characteristics PKT group
(N = 26)
N (%)
Control group
(N = 26)
N (%)
p-Value
Age, yrs
Mean (SD) 74.3 (2.9) 73.4 (4.1) 0.34
Gender
Male 15 (57.7) 13 (50) 0.56
Female 11 (42.3) 13 (50)
Cause of ESRD
Hypertensive nephropathy 10 (38.5) 6 (23.1) 0.23
Diabetes 4 (15.4) 6 (23.1) 0.48
Chronic glomerulonephritis 3 (11.5) 5 (19.2) 0.44
Hypertension 26 (100) 18 (69.2) 0.02
Diabetes 9 (34.6) 10 (38.5) 0.77
Dyslipemia 8 (30.8) 8 (30.8) 1.0
Ischemic heart disease 5 (19.2) 3 (11.5) 0.44
Peripheral arterial diseases 5 (19.2) 1 (3.8) 0.08
Cerebrovascular accident 1 (3.8) 1 (3.8) 1.0
Neoplasia 1 (3.8) 4 (15.4) 0.16
Hepatitis C virus infection 2 (7.7) 2 (7.7) 1.0
Donor characteristics PKT group
(N = 26)
N (%)
Control group
(N = 26)
N (%)
p-Value
Age, yrs
Mean (SD) 73.8 (4.1) 74.4 (5.1) 0.63
Gender
Male 14 (53.8) 17 (65.4) 0.39
Female 12 (46.2) 9 (34.6)
Cause of death
Acute cerebrovascular accident 20 (76.9) 21 (80.8) 0.73
Cranioencephalic trauma 4 (15.4) 3 (11.5) 0.68
Serum creatinine (mg/dl)a 0.7 (0.1) 0.7 (0.1) 0.98
GFR (MDRD) (ml/min/1.73 m2)a 90.4 (19.6) 94.2 (24.3) 0.54
Donor renal biopsy 16 (61.5) 20 (76.9) 0.23
Glomerulosclerosis same donor (N = 10)a 6.9 (3.7) 9.6 (5.2) 0.20
Glomerulosclerosis different donor (N = 6 y 10)a 7.4 (7.6) 5.9 (7.9) 0.71
HLA mismatches ≥3 5 (19.2) 4 (15.4) 0.71
Cold ischemia time (hours)a 21.4 (5.3) 21.6 (4) 0.88
Baseline immunosuppression with basiliximab + tacrolimus + mycophenolate mofetil + steroids 25 (96.2) 25 (96.2) 1.0
a Numbers reﬂect mean and SD.
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Initial cohort of study
(n=52)
Control group
(n=26)
Preemptive transplant group
 (n=26)
Patients alive with
preserved renal
function
(n=24)
Patients without preserved renal
function (n=7)
Month 0: 
-    Thrombosis (n=1) 
-    Ischemia-reperfusion (n=1) 
-    Death by ischemic cardiopathy
     with non-functioning graft (n=1)
Month 2: 
-    Death by sepsis with non-
     functioning graft (n=2)
-    Death by ischemic cardiopathy
     with functioning graft (n=1)
-    Urinary fistula (n=1)
Patients alive with
preserved renal
function
(n=19)
Patients without preserved renal
function (n=2)
Month 0: 
-         Death by sepsis with non-
          functioning graft (n=1)
Month 1: 
-         Death by liver failure with
          functioning graft (n=1)
End of follow-up
(n=22)
End of follow-up
(n=18)
Month 24: 
-Return to dialysis 
Month 24:- Death by sepsis with
                   functioning graft 
Month 43:- Death by ischemic
                  cardiopathy with
                  functioning graft 
Fig. 1 – Flow chart showing disposition of patients in the study.
in the control group, and the percentage of sclerotic glomeruli
was 6.3% (range 4.2–10%) and 5.8% (4–15%), respectively.
Median cold ischemia time was  21.4 ± 5.3 h (range 7–33.3)
in the PKT group and 21.6 ± 4 h (range 8.2–26.3) in the control
group (Fig. 1).
Main  outcomes
The actuarial 1-, 3-, and 5-year graft survival rates (death-
censored) were 96%, 96% and 96% in the PKT group and 76%,
68% and 68% in the control group (p = 0.02) (Fig. 2). Primary
non-function was observed in one patient (arterial throm-
bosis) in the PKT group and in three in the control group
(two cases of arterial thrombosis and one of venous throm-
bosis) (Table 2). Early graft loss (less than three months)
occurred in one patient in the PKT group (death from liver
failure with functioning graft) and in four patients in the
control group (one death with graft thrombosis, one death
from sepsis, one death from heart attack, and one urinary
ﬁstula).
The actuarial 1-, 3-, and 5-year patient survival rates were
92%, 78% and 78% in the PKT group and 83%, 83% and 83% in
the control group (Fig. 3). One patient in each group died with
a functioning graft. Four patients died in each group. Causes
of death in the PKT group were sepsis/multi-organ failure (2),
acute liver failure (1) and unclear (1). Causes of death in the
control group were sepsis/multi-organ failure (2) and cardiac
failure (2) (Table 2).
Secondary  outcomes
Delayed graft function was observed in one patient (3.8%)
in the PKT group and in nine (34.6%) in the control group
(p = 0.005). Six patients (23.1%) in the PKT group experienced
BPAR: four with acute cellular rejection and two with acute
humoral rejection. One patient (3.8%) in the control group
experienced acute cellular rejection (p = 0.043) (Table 3). After
a median follow-up of 34 months, 24 patients in the PKT group
and 19 in the control group had preserved renal function with-
out the need for dialysis (Fig. 1). At the end of the study, renal
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Table 2 – Causes of graft loss.
Cause PKT group
(N = 26)
N (%)
Control group
(N  = 26)
N (%)
p-Value
Primary non-function 1 (3.8)a 3 (11.5)b 0.29
Delayed graft function 1 (3.8) 9 (34.6) 0.005
Early graft loss (≤3 months) 1 (3.8)c 4 (15.4)d 0.15
Acute rejection 6 (23.1) 1 (3.8) 0.043
Cellular 4 (66.7) 1 (100)
Humoral 2 (33.3) 0 (0)
Exitus with a functioning graft 3 (75) 1 (25) 0.15
Total number of deaths 4  (15.4)e 4 (15.4)f 1.0
Return to dialysis 0  (0) 4  (15.4) 0.03
a Arterial thrombosis.
b Venous thrombosis (1), arterial thrombosis (2).
c Death from liver disease with functioning graft.
d Death from infection (1), death from ischemic heart disease (1), venous thrombosis (1), urinary ﬁstula (1).
e Infection (2), liver disease (1), cardiovascular disease (1).
f Infection (2), ischemic heart disease (2).
function was similar in the two groups (PKT: Scr 1.7 ± 0.8 mg/dl
and GFR-MDRD 42.2 ± 18.3 ml/min/1.73 m2; control: Scr
1.6 ± 0.9 mg/dl and GFR-MDRD 40.4 ± 13.8 ml/min/1.73 m2).
Proteinuria was 0.6 g/24 h in the PKT group and 0.3 g/24 h in
the control group (p = 0.08) (Table 3 and Fig. 4). No patients
in the PKT group and four in the control group returned to
dialysis (p = 0.03).
During follow-up, immunosuppression consisted of a com-
bination of tacrolimus, mycophenolic acid and steroids in 67%
of all patients. Other immunosuppressive regimens used were
similar in the two groups. Tacrolimus levels at the end of
follow-up were 6.9 ± 2.3 in the PKT group and 7.5 ± 2.6 ng/ml
in the control group (p = 0.43).
CMV  infections and urinary tract infections were similar
in the two groups. Urological complications and tumor inci-
dences were also similar in the two groups, while a slightly
higher number of cardiovascular complications and periph-
eral arterial diseases were observed in the PKT group (p = 0.06)
(Table 4).
Clinical  factors  associated  with  graft  survival
In the univariate analysis including age, time on dialysis,
delayed graft function, HLA incompatibility, belonging to PKT
group, diabetes mellitus, serum creatinine at month 6, pro-
teinuria at month 6, and the difference in GFR between month
6 and end of study, only those belonging to PKT group were
associated with improved outcome (p = 0.049). Multivariate
logistic regression analysys was performed and the factor
belonging to PKT group did not reach statistical signiﬁcance
(HR = 0.18; 95% CI, 0.03–1.02; p = 0.053) (Table 5).
Discussion
The shortage of organs is a major hurdle in kidney transplanta-
tion, and one solution to the problem is to extend the age of the
donor. However, organs from older donors are often discarded
due to the macroscopic appearance of the parenchyma or
Table 3 – Evolution of renal function and proteinuria.
Variable PKT group
(N = 24)
Control  group
(N = 19)
p-Value
Serum creatinine (mg/dl)
6 months (PKT = 24/CG = 19 patients) 1.7 ± 0.7 (0.9–3.9) 1.5 ± 0.4 (0.8–2.5) 0.23
12 months (PKT = 24/CG = 19 patients) 1.5 ± 0.4 (1–2.8) 1.5 ± 0.5 (0.9–3.1) 0.86
End of follow up (PKT = 22/CG = 18 patients) 1.7 ± 0.8 (0.7–4.2) 1.6 ± 0.9 (0.8–5) 0.78
GFR (MDRD) (ml/min/1.73 m2)
6 months (PKT = 24/CG = 19 patients) 39.5 ± 14.6 (15.2–73) 41.9 ± 11.9 (19.2–72.1) 0.58
12 months (PKT = 24/CG = 19 patients) 42.7 ± 11.7 (21.9–65) 41.7 ± 11.2 (14.7–58) 0.80
End of follow up (PKT = 22/CG = 18 patients) 42.2 ± 18.3 (13.7–87) 40.4 ± 13.8 (8.4–72.1) 0.72
Decline in GFR (6 months – end of follow-up) (ml/min/1.73 m2 per year) +0.9 ± 0.5 (−5.9 to 12.8)
1.2 (−2.9 to 3.8)
+0.1 ± 3.4 (−6.9 to 5.3)
0 (−2.1 to 2.5)
0.52
Proteinuria (g/24 h)
6 months (PKT = 24/CG = 19 patients) 0.4 (0.2–0.9) 0.4 (0.2–0.6) 0.31
12 months (PKT = 24/CG = 19 patients) 0.5 (0.2–1) 0.3 (0.2–0.5) 0.09
End of follow-up (PKT = 22/CG = 18 patients) 0.6 (0.3–1) 0.3 (0.2–0.4) 0.08
Follow-up (months) 35.5 ± 20.1 (5–67) 32 ± 20.9 (2–66) 0.58
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Table 4 – Major surgical and medical complications.
Complication PKT group
(N = 26)
N (%)
Control  group
(N = 26)
N (%)
p-Value
Infection 10 (41.7) 9 (47.4) 0.70
Urinary tract 3 (30) 4 (44.4) 0.45
CMV 3 (30) 4 (44.4) 0.45
Urological problem 10 (38.5) 10 (38.5) 1.0
Urinary ﬁstula 2 4
Wound dehiscence 1  1
Seroma 3 2
Arterial stenosis 2  2
Ureter stenosis 2 1
Tumor 2 (8.3)a 2 (10.5)b 0.80
Cardiovascular disease
Hypertension 22 (91.7) 17 (89.5) 0.80
Diabetes 10 (41.7) 7 (36.8) 0.75
Dyslipemia 11 (45.8) 11 (57.9) 0.43
Ischemic heart disease 7 (29.2) 3 (15.8) 0.30
Cerebrovascular accident 1 (4.2) 0 0.36
Chronic limb ischemia 4 (16.7) 0 0.06
a Colon (1), Kaposi’s sarcoma (1).
b Skin (1), Kaposi’s sarcoma (1).
Table 5 – Risk factors for graft survival.
Factor Univariate
analysis
HR (95% CI)
p-Value Multivariate
analysis
HR (95% CI)
p-Value
Age 1.1 (0.90–1.40) 0.27 1.1 (0.94–1.46) 0.14
Delayed graft function 2.1 (0.33–13.7) 0.42
HLA incompatibilities 1.5 (0.73–3.27) 0.25 1.5 (0.64–3.60) 0.33
PKT group 0.2 (0.03–0.99) 0.049 0.18 (0.03–1.02) 0.053
Acute rejection 0.9 (0.39–2.06) 0.90
Serum creatinine at 6 months 4.1 (0.47–35.8) 0.39
Proteinuria at 6 months 1.5 (0.6–3.8) 0.42
major vessels. In addition, a large number are often discarded
due to the lack of compatible recipients among elderly patients
undergoing chronic dialysis.13 A possible solution to avoid this
wastage of kidneys potentially suitable for transplantation
could be the performance of PKT in carefully selected elderly
patients. Patient and graft survival are longer for patients
undergoing PKT than for those transplanted when receiving
dialysis, and time spent on dialysis prior to transplantation
signiﬁcantly affects graft and patient outcome.8,9 In a study
of 1849 kidney recipients, including 385 PKTs, patient sur-
vival at 5 years was higher in PKT than in non-PKT patients.
With deceased donors, patient survival was 92.6% and 76.6%,
respectively (p = 0.001), and with living donors, patient survival
was 93.3% and 89.5%, respectively (p = 0.02). Graft survival was
also higher among the PKT patients.14 Several other studies
have also shown better results when performing PKT as com-
pared to transplantation after the onset of chronic dialysis.
Nevertheless, no studies have analyzed the performance of
PKT in elderly patients using kidneys from elderly deceased
donors. This policy would gather the beneﬁts linked to PKT
and the use of valid organs that otherwise would be discarded.
Our pilot study demonstrates that PKT in very elderly patients
(mean age 74.3 ± 2.9 years) using kidneys from very elderly
deceased donors (mean age 73.8 ± 4.1 years) offers excellent
results. Graft survival was signiﬁcantly better in PKT patients
as compared to that of a control group of elderly patients who
received kidneys from elderly deceased donors after having
started chronic dialysis. There were no differences between
both groups regarding patient survival. By univariate analysis,
belonging to PKT group was the only factor associated with
an improved outcome, although it did not reach statistical
signiﬁcance by multivariate analysis (Table 5).
The reason for improved graft survival with PKT is not
completely clear. Several studies have shown a negative
impact of waiting time on dialysis, with a directly pro-
portional relationship to the risk of graft loss and shorter
patient survival.15 The time on dialysis also inﬂuences chronic
allograft nephropathy.8 The exact reasons for this negative
effect remain unclear, but several potential explanations
have been postulated, such as an increase of persistent pro-
inﬂammatory and pro-atherogenic molecules, malnutrition,
immune system disorders and inadequate clearance of toxic
metabolites.16,17 The preservation of residual renal function
may inﬂuence the improvement in survival. Recent studies
have found no clear evidence on this factor. On the other hand,
differences in the rate of immediate or delayed graft function,
or in the rate of acute rejection, could inﬂuence better out-
comes of PKT. We found that our elderly PKT patients had a
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Fig. 2 – Kaplan–Meier estimates of (A) death-censored graft
survival and (B) non-death-censored graft survival.
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Fig. 4 – Renal function over time in 26 PKT patients and 26
controls, shown as (A) median Scr levels and (B) median
GFR.
signiﬁcantly higher rate of immediate graft function (92% vs
53%) and a signiﬁcantly lower rate of delayed graft function
(3.8% vs 34.6%), as compared to control patients. On the con-
trary, we found a signiﬁcantly higher rate of BPAR among our
PKT patients (23.1% vs 3.8% in the control group). Some stud-
ies have shown a signiﬁcantly lower rate of BPAR within the
ﬁrst six months post-transplantation in PKT patients.18,19 In
contrast, in another study of 1463 kidney transplants more
patients experienced an acute rejection episode in the PKT
group,20 which the authors tentatively attributed to poor drug
compliance or to the absence of the immunosuppressive effect
of the uremic state.6 Although age was associated with a
decrease in the function of the immune system and therefore
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a decrease in the rate of acute rejection, however the impact
of acute rejection on graft loss has been reported to be more
pronounced in elderly patients, independent of graft quality.21
However, in all these studies graft survival was higher in the
PKT group.20 Although we  should not forget that the informa-
tion in these studies is biased toward patients who received a
kidney transplant from living donor. There is little information
in the literature on the incidence of acute rejection and its evo-
lution in older patients who  receive the anticipated renal graft
from cadaver or living. Recent ﬁndings from our group provide
new information in the ﬁeld of immunology (imbalance of
the different lymphocyte populations, immunoglobulins and
complement) in dialysis patients and its inﬂuence on the
development of infections.22,23 These ﬁndings should lead to
new lines of research aimed at knowledge and behavior of
lymphocyte subsets in patients with advanced chronic kid-
ney disease and dialysis population and its possible inﬂuence
on acute rejection. Taken together, these ﬁndings suggest that
PKT may have a long-term advantage regardless of acute rejec-
tion episodes.
Since our study is the ﬁrst to analyze PKT in very elderly
patients using very elderly donors, more  studies are required
to conﬁrm our results and to gain insights into the inﬂuence
of uremia and chronic dialysis in the risk of acute rejection in
this population.
Our study has several limitations, including a relatively
small sample size. It was conducted at a single center, and
our criteria for including patients – GRF < 15 ml/min and 25%
progression in renal failure over the past year24 – may rule
out extrapolating our ﬁndings to other centers using differ-
ent criteria. Furthermore, we did not evaluate residual renal
function, which may confer a survival beneﬁt and which
merits investigation in future studies. Nevertheless, although
deceased donor organs are, for ethical reasons, reserved for
patients on dialysis, our experience has shown that PKT can
be an option for patients with non-dialysis ESRD with no
detriment to dialysis patients on the waiting list. This pol-
icy may both provide non-dialysis elderly patients with the
opportunity for a PKT; with the promise of excellent results,
and also help overcome the problem of organ shortages by
using kidneys destined to be discarded due to a lack of elderly
recipients. The focus of clinicians should be on shortening
transplant waiting times for elderly patients using preemp-
tive transplantation whenever possible. The kidneys from
deceased very old donors can be successfully transplanted in
ESRD non-dialysis elderly recipient when there are not other
very old candidates in the waiting list.
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